University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
J

Advances in the CLL Frontline Therapy: BTK Inhibitors vs. Chemoimmunotherapy, Venetoclax vs. Chemoimmunotherapy

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jennifer Woyach
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jennifer Woyach
154 views
May 14, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey
CLL Therapy in 2019
13:16

Advances in the CLL Frontline Therapy: BTK Inhibitors vs. Chemoimmun…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Woyach

154 views
07:09

The Big Question in CLL Frontline Therapy: How to Choose Between Ibr…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Woyach

282 views
24:51

2020 Update on Combination Therapies in R/R CLL: Venetoclax +R, Vene…

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Davids

56 views